Health Canada had advised that beginning on October 1, 2018, it would implement certain proposals for its prescription drug product transparency initiatives. Health Canada will start providing Regulatory Decisions Summaries (RDSs) for approvals of certain drugs approved on the basis of abbreviated new drug submissions (ANDSs). For submissions accepted into review on or after October 1, 2018, Health Canada now provides the following information:
- The Submissions Under Review List now includes sponsor names and submission class for new drug submissions and supplemental new drug submissions; and
- The new, separate Generic Submissions Under Review (GSUR) List includes a list of the generic submissions under review by medicinal ingredient.
Related Publications & Articles
-
Health Canada consultation on revised biosimilar guidance: no requirement for comparative clinical efficacy and safety trials
On June 10, 2025, Health Canada launched a consultation on its Draft Guidance Document: Information and Submission Requirements for Biosimilar Biologic Drugs which includes numerous proposed revisions...Read More -
Update on biosimilars in Canada – June 2025
This article provides an update on developments in the biosimilar space in Canada—regulatory, approvals, pending submissions, litigation, and market access.Read More -
Health Canada must redetermine exemption requests for psilocybin (magic mushroom)-assisted psychotherapy training
TheraPsil, a patient advocacy organization, and 73 healthcare practitioners (HCPs) have succeeded in the Federal Court of Appeal to overturn the refusal of the Minister of Mental Health and Addictions...Read More